ASX announcement link here.
Read more about Avita Medical Update to Shareholders
Pharmaceutical company Pharmaxis (ASX:PXS) today announced that the Scottish Medicines Consortium (SMC) has accepted Bronchitol® (mannitol dry powder for inhalation) for use by the National Health Service in Scotland. Bronchitol is licensed for the treatment of adult cystic fibrosis (CF) patients aged 18 years and above as an add-on therapy to best standard of care.
Biota Pharmaceuticals Inc. (“Biota”) (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate (“LANI”), its long-acting neuraminidase inhibitor being developed for the treatment of influenza.
Please find the ASX announcement here.
Read more about Bioxyne Ltd – Sale of HI-164OV Hunter Immunology Pty Ltd
Bioxyne Limited (ASX code: BXN or the Company) advises that subsequent to the execution of a non-binding Heads of Agreement (HOA) to sell its HI-164 oral Vaccine project together with all of its Intellectual properties (IP) to Mariposa Health Limited (MHL), Dr. Phillip Comans has stepped down as Chief executive Officer of the Company.
Read more about Bioxyne Ltd CEO Steps Down
Chairman’s Address to 2013 Annual General Meeting here.
Read more about Pharmaxis – AGM presentation and results
Read more about Avita Medical – Results of Annual General Meeting
Leading Australian life sciences investment group BioScience Managers today confirmed it will vote against the remuneration report of spray-on skin company Avita Medical Limited (ASX:AVH) at the company’s AGM on Friday 22 November.
Read more about Avita Medical Facing First Strike
Financial report 2013 link here.
Read more about Avita Medical Annual Report to shareholders